TGFB1 and diabetic kidney disease: TGF-β1/Smad as a key signaling pathway in the pathogenesis of DKD, affects disease progression by inducing and promoting both inflammation and fibrosis due to its large and complex network of mechanisms, and DKD can be treated by rebalancing TGF-β1/Smad signaling (240–242).